# Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Source: https://onco.cc/trials/nct02981368/  
OnCo record `nct02981368` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.

## Summary

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer is a phase 2/3 interventional study registered as NCT02981368 by Progenics Pharmaceuticals, Inc., with 385 participants recorded, started 2016-11 and reaching its primary completion in 2018-07. Interventions recorded: 18F-DCFPyL Injection, PET/CT imaging. Conditions recorded: Prostate Cancer.

Linked to the drug Piflufolastat F-18 / Pylarify TruVu because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02981368
- Phase: 2/3
- Setting: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
- Sponsor: Progenics Pharmaceuticals, Inc.
- Enrolled: 385

## Sources

- ClinicalTrials.gov NCT02981368: https://clinicaltrials.gov/study/NCT02981368

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/)
- companies: [Lantheus](https://onco.cc/companies/lantheus/)

---
JSON: https://onco.cc/api/v1/entities/nct02981368.json